

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

Date: (Filing No. H- )

**HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES**

Reproduced and distributed under the direction of the Clerk of the House.

**STATE OF MAINE  
HOUSE OF REPRESENTATIVES  
131ST LEGISLATURE  
SECOND REGULAR SESSION**

COMMITTEE AMENDMENT “ ” to H.P. 432, L.D. 663, “An Act to Require Health Insurance Coverage for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome”

Amend the bill by striking out everything after the enacting clause and inserting the following:

**Sec. 1. 24-A MRSA §4320-W** is enacted to read:

**§4320-W. Coverage for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome**

A carrier offering a health plan in this State shall provide coverage for treatment of pediatric postinfectious neuroimmune disorders including pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Treatments that must be covered include, but are not limited to, long-term antibiotics, intravenous immunoglobulin therapy, steroids, plasmapheresis and psychopharmacological interventions. Coverage may not be excluded due to the diagnosis of autoimmune encephalopathy or autoimmune encephalitis.

**Sec. 2. Application.** The requirements of this Act apply to all policies, contracts and certificates executed, delivered, issued for delivery, continued or renewed in this State on or after January 1, 2025. For purposes of this Act all contracts are deemed to be renewed no later than the next yearly anniversary of the contract date.

**Sec. 3. Appropriations and allocations.** The following appropriations and allocations are made.

**ADMINISTRATIVE AND FINANCIAL SERVICES, DEPARTMENT OF  
State Benefit Mandate Defrayal Z373**

Initiative: Provides ongoing funding for the cost of the benefit mandate providing coverage for treatment of pediatric postinfectious neuroimmune disorders including pediatric

**COMMITTEE AMENDMENT**

1 autoimmune neuropsychiatric disorders associated with streptococcal infections and  
2 pediatric acute-onset neuropsychiatric syndrome, beginning January 1, 2025.

3	<b>GENERAL FUND</b>	<b>2023-24</b>	<b>2024-25</b>
4	All Other	\$0	\$395,000
5			
6	GENERAL FUND TOTAL	<u>\$0</u>	<u>\$395,000</u>

7

8       Amend the bill by relettering or renumbering any nonconsecutive Part letter or section  
9 number to read consecutively.

10

### SUMMARY

11       This amendment is the minority report of the committee. The amendment changes the  
12 applicability date for the requirements in the bill to be incorporated into health plans to  
13 those health plans issued or renewed on or after January 1, 2025 and changes the statutory  
14 allocation. The amendment also adds an appropriation to provide ongoing funding for the  
15 costs of the benefit mandate defrayal required by federal law.

16

### FISCAL NOTE REQUIRED

17

(See attached)